Announcement
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) 28 Sep - Morepen submitted first U.S. ANDA for Sitagliptin Tablets USP in 25 mg, 50 mg, 100 mg strengths.
Source: Bse
Morepen Laboratories Limited (MOREPENLAB)
Small CapPharma stocks · Small cap · NSE
Morepen Laboratories Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result04 Aug, 07:13 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
77BullishSMA20 +14.6% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 61
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
MOREPENLABD candles · FIT view+166.7%Latest close ₹115.42 on 2026-10-21
Bar
-3.8%
RSI
44
MACD hist
-2.92
52W pos
70%
2026-10-21O ₹119.99H ₹123.50L ₹115.42C ₹115.42Vol 47.8L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
MOREPENLABNifty PharmaNifty 500
- MOREPENLAB
- +103.1%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +109.6 pp
Chart stats
21 Oct 2026- From 52W high
- -23.4%
- 52W range position
- 70%
- ATR (14)
- 7.1%
- Volume vs 20D
- 0.33x
- Avg traded value
- ₹181 Cr
- 20D price channel
- ₹115.4 - ₹150.7
₹150.7
₹33.1 - ₹150.7
₹8.2
Latest completed session
20-session average
65.9% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · OVERVALUED20
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent100
Revenue +34.1% · PAT +409.1% YoY
Technical
Bullish77
Price trend and sector-relative-strength timing.
Valuation
Legacy model-951.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence70
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 100/100Rev +34% YoY · PAT +409% YoY · margin expansion · +18% QoQ · operating leverage
Filed 04 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹570 Cr | +34.1% | +17.5% |
| EBITDA | ₹83 Cr | +245.8% | +245.8% |
| Operating margin | 14.0% | +800 bps | +900 bps |
| PAT | ₹56 Cr | +409.1% | +250.0% |
| PAT margin | 9.8% | +723 bps | +652 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 63.10
- P/B
- 5.92
- EV/EBITDA
- 34.64
- Market Cap
- 7413.00Cr
Profitability
- ROE
- 5.33%
- ROCE
- 8.05%
- ROA
- 7.93%
- Dividend Y
- 0.15%
Growth (CAGR)
- Revenue 5Y
- 9.00%
- EPS 5Y
- -8.00%
- Revenue 3Y
- 8.00%
- EPS 3Y
- 18.00%
Balance Sheet
- Debt/Equity
- 0.17
- Interest Coverage
- 10.82×
- Altman Z
- 8.51
- Book Value
- 22.80
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 5/5
- OCF
- 33.00 Cr
- EPS TTM
- 2.57
Shareholding
- Promoter Hold
- 35.66%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 97%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 570+17.5% vs prev
Net Profit
₹ CrLatest: 56.0+250.0% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 44. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~12.8% over last month) — short-term momentum positive.
- RSI(14) at 44 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 23% off 52W high · 249% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
98
RS percentile
Stage 2 UptrendEstablished S2
1M return
-5.7%
3M return
+103.1%
6M return
+170.4%
1Y return
+136.9%
RS 1D
0
RS 20D
0
Sector rank
#1
Industry rank
#14
Stage evidence
- Price is 65.6% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +19.7%.
- Both 3-month and 6-month returns are positive.
50-DMA
price above
200-DMA
price above
S2 entered
24 Jun 2026
S2 age
83 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 250.02-4.11%
RS vs Nifty 500250
Valuation & peers
U-Score 20 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 20 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation0/30
Growth4/25
Quality0/20
Balance Sheet8/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
-1
Raw sum
20
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
20/100 · legacy band OVERVALUED
Positive drivers
- Piotroski is strong at 8/9.
- Balance sheet contributes 8/15 to the score.
- Cash flow contributes 4/10 to the score.
Main drags
- Penalty bucket subtracts 1 points.
- Fair-value margin of safety is negative at -951.8%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
63.1
PB
5.9
EV/EBITDA
34.6
ROE
5.3%
ROCE
8.1%
FCF Yield
—
Debt/Equity
0.2
MoS
-951.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
20
Previous: 20
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-951.8%
Previous: -1007.0%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
20
20
20
20
20
20
20
20
20
20
20
20
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹36.31
-217.9% MoS
Growth-justified P/E
4.3
Growth-justified Value
₹10.97
-951.8% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
SUVEN
Small
Suven Life Sciences Limited
Healthcare Services
match 166
29
—
-81.5%
—
OVERVALUED
SENORES
Small
Senores Pharmaceuticals Limited
Healthcare Services
match 165
35
48.2
13.4%
-2%
WATCHLIST
ORCHPHARMA
Small
Orchid Pharma Limited
Healthcare Services
match 165
33
320.0
1.5%
-846%
WATCHLIST
KOVAI
Small
Kovai Medical Center & Hospital Limited
Healthcare Services
match 165
46
113.0
22.2%
-146%
FAIR VALUE
SMSPHARMA
Small
SMS Pharmaceuticals Limited
Healthcare Services
match 163
35
43.7
14.3%
-27%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Morepen Laboratories Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
70Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 63rd percentile of the scored universe and 50th percentile within Pharma. Main check: financial discipline is weak at 42/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
103 docs text-extracted · 34 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
63rd percentile
overall median 67 · Pharma: 50th pctile, median 70 · Small: 65th pctile, median 66
Evidence depth
Financial-only
103 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
42
weak · capital discipline
Results
74
acceptable · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸5 years of positive FCF.
- ▸3/4 latest quarters had positive YoY revenue growth.
- ▸3/4 latest quarters had positive YoY PAT growth.
Trust risks
- ▸ROE is low at 6.2%.
- ▸ROCE trend is -5.3%.
- ▸2 older quarters in the 8-quarter window had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Morepen Laboratories Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement Under Regulation 30 Of The SEBI (LODR) 7 Sep - First phase capacity expansion completed ahead of schedule; reactor capacity rises from 535 KL to 614 KL.
Source: Bse
Annual report
Business Responsibility and Sustainability Reporting (BRSR) 2 Sep - Morepen Laboratories filed its FY2025-26 BRSR as part of the annual report.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
Annual report
Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Sep - Newspaper publication for completion of dispatch of the notice of 41st AGM and Annual report for the FY 2025-26
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.